Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Omega Therapeutics Inc (OMGA)

Omega Therapeutics Inc (OMGA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,715
  • Shares Outstanding, K 55,155
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -97,430 K
  • 60-Month Beta 1.83
  • Price/Sales 47.69
  • Price/Cash Flow N/A
  • Price/Book 2.54
Trade OMGA with:

Options Overview Details

View History
  • Implied Volatility 156.93% ( -12.88%)
  • Historical Volatility 76.52%
  • IV Percentile 75%
  • IV Rank 42.86%
  • IV High 301.96% on 10/31/23
  • IV Low 48.17% on 09/13/23
  • Put/Call Vol Ratio 3.67
  • Today's Volume 196
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 2,745
  • Open Int (30-Day) 2,500

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.49
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +6.64%
on 04/16/24
3.77 -36.07%
on 03/28/24
-1.21 (-33.43%)
since 03/15/24
3-Month
2.26 +6.64%
on 04/16/24
4.46 -45.96%
on 03/01/24
-1.28 (-34.78%)
since 01/16/24
52-Week
1.30 +85.38%
on 11/01/23
10.09 -76.11%
on 05/23/23
-5.15 (-68.12%)
since 04/14/23

Most Recent Stories

More News
Why Novo Nordisk Stock Crushed the Market Today

The company just boosted its research and development efforts.

NVO : 123.45 (-0.36%)
OMGA : 2.41 (-4.17%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 17.34 (-2.80%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 48.23%: Read This Before Placing a Bet

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 48.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

OMGA : 2.41 (-4.17%)
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue Estimates

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

OMGA : 2.41 (-4.17%)
RVNC : 3.81 (-4.03%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 17.34 (-2.80%)
EVLO : 0.0460 (+2.22%)
FHTX : 6.03 (-5.63%)
MRNA : 103.79 (-0.07%)
OMGA : 2.41 (-4.17%)
SANA : 8.41 (-1.64%)
MCRB : 0.6361 (+2.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 2.68
2nd Resistance Point 2.56
1st Resistance Point 2.49
Last Price 2.41
1st Support Level 2.30
2nd Support Level 2.18
3rd Support Level 2.11

See More

52-Week High 10.09
Fibonacci 61.8% 6.73
Fibonacci 50% 5.70
Fibonacci 38.2% 4.66
Last Price 2.41
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar